- Home
- PSNL vs ZYME Comparison
PSNL vs ZYME Comparison
Compare PSNL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ZYME |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ZYME |
|---|---|---|
| Price | $15.72 | $26.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $15.17 | ★ $43.23 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | 33.33 |
| EPS | N/A | ★ 1.08 |
| Revenue | $69,648,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $27.28 | $216.20 |
| Revenue Next Year | $24.60 | $7.81 |
| P/E Ratio | ★ N/A | $24.65 |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $4.96 | $21.52 |
| 52 Week High | $18.89 | $31.97 |
Technical Indicators
Market Signals| Indicator | PSNL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 41.75 |
| Support Level | $15.51 | $25.21 |
| Resistance Level | $16.49 | $27.40 |
| Average True Range (ATR) | 0.24 | 1.41 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 31.97 | 5.69 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.